GeoVax Labs (GOVX) 10-Q 8 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 08, 2018
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	832,489
Trading Symbol	govx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		196,903,476
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
ASSETS
Cash and cash equivalents	$ 511,242	$ 312,727
Grant funds and other receivables	14,757	59,758
Prepaid expenses and other current assets	70,188	75,589
Total current assets	596,187	448,074
Property and equipment, net	16,270	31,151
Deposits	11,010	11,010
Total assets	623,467	490,235
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)
Accounts payable	147,947	77,581
Accrued expenses (Note 6)	1,149,758	733,711
Current portion of note payable	7,294
Total current liabilities	1,304,999	811,292
Note payable, net of current portion	42,706
Total liabilities	1,347,705	811,292
Commitments (Note 8)
Stockholders’ equity (deficiency):
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 178,403,476 and 106,736,810 at September 30, 2018 and December 31, 2017	178,403	106,737
Additional paid-in capital	36,830,813	35,589,911
Accumulated deficit	(39,842,539)	(37,916,790)
Total stockholders’ equity (deficiency)	(724,238)	(321,057)
Total liabilities and stockholders’ equity (deficiency)	623,467	490,235
Series B Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	76,095	76,095
Series C Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	842,990	842,990
Series D Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock		980,000
Series E Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	$ 1,190,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	178,403,476	106,736,810
Common stock, shares outstanding (in shares)	178,403,476	106,736,810
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	100	100
Preferred stock, shares outstanding (in shares)	100	100
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	2,570	2,570
Preferred stock, shares outstanding (in shares)	2,570	2,570
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	0	1,000
Preferred stock, shares outstanding (in shares)	0	1,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	1,200	0
Preferred stock, shares outstanding (in shares)	1,200	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Grant and collaboration revenue	$ 349,344	$ 247,994	$ 663,908	$ 895,866
Operating expenses:
Research and development	557,696	498,200	1,416,892	1,568,093
General and administrative	458,974	340,143	1,175,399	985,001
Total operating expenses	1,016,670	838,343	2,592,291	2,553,094
Loss from operations	(667,326)	(590,349)	(1,928,383)	(1,657,228)
Other income (expense):
Interest income	1,058	1,592	4,092	3,249
Interest expense	(625)		(1,458)
Total other income (expense)	433	1,592	2,634	3,249
Net loss	$ (666,893)	$ (588,757)	$ (1,925,749)	$ (1,653,979)
Basic and diluted:
Loss per common share (in dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.03)
Weighted averages shares outstanding (in shares)	167,407,100	67,000,857	149,761,230	60,757,109

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (1,925,749)	$ (1,653,979)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	14,881	20,694
Stock-based compensation expense	275,425	43,535
Changes in assets and liabilities:
Grant funds receivable	45,001	(61,821)
Prepaid expenses and other current assets	62,544	49,855
Accounts payable and accrued expenses	486,413	361,695
Total adjustments	884,264	413,958
Net cash used in operating activities	(1,041,485)	(1,240,021)
Cash flows from investing activities:
Purchase of property and equipment		(4,350)
Net cash used in investing activities		(4,350)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	1,190,000	980,000
Net proceeds from sale of common stock		154,167
Proceeds from issuance of note payable	50,000
Net cash provided by financing activities	1,240,000	1,134,167
Net increase (decrease) in cash and cash equivalents	198,515	(110,204)
Cash and cash equivalents at beginning of period	312,727	454,030
Cash and cash equivalents at end of period	$ 511,242	$ 343,826

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Convertible preferred stock (in shares)	1,000	178
Conversion of stock, shares issued (in shares)	66,666,666	11,862,000

Note 1 - Description of Busines

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Basis of Accounting [Text Block]	2. The accompanying condensed consolidated financial statements at September 30, 2018 three nine September 30, 2018 2017 not 10 December 31, 2017. not Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations into January 2019. not may not

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. We disclosed in Note 2 10 December 31, 2017 no 10 In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. five 2014 09 January 1, 2018; no In May 2017, 2017 09, Scope of Modification Accounting 2017 09 718, 2017 09 1 2 718 2017 09 January 1, 2018; no In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07 718 December 15, 2018, 2018 07 There have been no nine September 30, 2018, 10 December 31, 2017,

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 276.0 277.5 September 30, 2018 2017,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of September 30, 2018 December 31, 2017: September 30, 2018 December 31, 2017 Laboratory equipment $ 530,306 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 674,596 Accumulated depreciation and amortization (658,326 ) (643,445 ) Property and equipment, net $ 16,270 $ 31,151

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of September 30, 2018 December 31, 2017: September 30, 2018 December 31, 2017 Accrued management salaries $ 816,715 $ 532,615 Accrued directors’ fees 265,420 182,620 Other accrued expenses 67,623 18,476 Total accrued expenses $ 1,149,758 $ 733,711

Note 7 - Note Payable

Note 7 - Note Payable	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	7. On February 28, 2018, five $50,000. 5%, second 0 2018, $10,417 2019, $12,500 2020, 2021 2022, $2,083 2023. five 178,571 9 three nine September 30, 2018 $625 $1,458,

Note 8 - Commitments

Note 8 - Commitments	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. We lease approximately 8,400 December 31, 2019, December 31, 2022. September 30, 2018, $200,402, $39,136 2018 $161,266 2019. may September 30, 2018, $209,000,

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Series B Convertible Preferred Stock As of September 30, 2018, 100 may $0.35 285,714 nine September 30, 2018, no Series C Convertible Preferred Stock As of September 30, 2018, 2,570 may $0.015 171,349,733 nine September 30, 2018, no Series D Convertible Preferred Stock As of September 30, 2018, no nine September 30, 2018, 1,000 66,666,666 Series E Convertible Preferred Stock In March 2018, 600 $1,000 $590,000. September 2018, 600 $600,000. Each share of Series E Preferred Stock is entitled to a liquidation preference equal to the initial purchase price, has no not $0.02544 may, In connection with the Series E Preferred Stock issuance in September 2018, 47,169,812 $0.02544 six 3 may, not We assessed the Series E Preferred Stock under ASC Topic 480, Distinguishing Liabilities from Equity 480” 815, Derivatives and Hedging 815” 470, Debt 470” 815 not 815. During the nine September 30, 2018, no Common Stock Transactions As discussed above, during the nine September 30, 2018, 66,666,666 1,000 In February 2018, 5,000,000 Stock Options The following table presents a summary of our stock option transactions during the nine September 30, 2018: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2017 7,024,275 $ 0.29 Granted 3,000,000 0.03 Exercised -- -- Forfeited or expired (169,334 ) 2.46 Outstanding at September 30, 2018 9,854,941 $ 0.17 Exercisable at September 30, 2018 4,890,618 $ 0.29 Stock Purchase Warrants On February 28, 2018, 7, five 178,571 $0.042 September 5, 2018, three 47,169,812 $0.02544 no September 30, 2018. Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $85,370 $132,569 three nine September 30, 2018, $14,433 $43,535 three nine September 30, 2017, September 30, 2018, $145,230 1.9 Additionally, during the three nine September 30, 2018 $57,143 $142,856, September 30, 2018, $57,143 2018 first 2019.

Note 10 - Income Taxes

Note 10 - Income Taxes	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Because of our historically significant net operating losses, we have not 382

Note 11 - Grants and Collaborat

Note 11 - Grants and Collaboration Revenue	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Government Grants and Contracts [Text Block]	11. We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three nine September 30, 2018, $340,716 $650,280, $247,994 $800,866, 2017. September 30, 2018, $2,873,542 During the three nine September 30, 2018, $8,628 $13,628, third 0 $95,000, 2017.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	12. In October 2018, 5,000,000 $129,750 six In October 2018, 7,500,000 $56,250 September 30, 2018. $127,500 June 30, 2019. During October 2018, 90 6,000,000

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, 2018 December 31, 2017 Laboratory equipment $ 530,306 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 674,596 Accumulated depreciation and amortization (658,326 ) (643,445 ) Property and equipment, net $ 16,270 $ 31,151

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2018 December 31, 2017 Accrued management salaries $ 816,715 $ 532,615 Accrued directors’ fees 265,420 182,620 Other accrued expenses 67,623 18,476 Total accrued expenses $ 1,149,758 $ 733,711

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2017 7,024,275 $ 0.29 Granted 3,000,000 0.03 Exercised -- -- Forfeited or expired (169,334 ) 2.46 Outstanding at September 30, 2018 9,854,941 $ 0.17 Exercisable at September 30, 2018 4,890,618 $ 0.29

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares shares in Millions	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	276	277.5

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property and equipment, gross	$ 674,596	$ 674,596
Accumulated depreciation and amortization	(658,326)	(643,445)
Property and equipment, net	16,270	31,151
Laboratory Equipment [Member]
Property and equipment, gross	530,306	530,306
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accrued management salaries	$ 816,715	$ 532,615
Accrued directors’ fees	265,420	182,620
Other accrued expenses	67,623	18,476
Total accrued expenses	$ 1,149,758	$ 733,711

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual) - USD ($)	Feb. 28, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Proceeds from Notes Payable, Total				$ 50,000
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	178,571
Interest Expense, Total		$ 625		1,458
Common Stock Purchase Warrants [Member]
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	178,571
Senior Notes [Member]
Debt Instrument, Term	5 years
Proceeds from Notes Payable, Total	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	$ 0
Long-term Debt, Maturities, Repayments of Principal in Year Two	10,417
Long-term Debt, Maturities, Repayments of Principal in Year Three	12,500
Long-term Debt, Maturities, Repayments of Principal in Year Four	12,500
Long-term Debt, Maturities, Repayments of Principal in Year Five	12,500
Long-term Debt, Maturities, Repayments of Principal after Year Five	$ 2,083
Interest Expense, Total		$ 625		$ 1,458

Note 8 - Commitments (Details T

Note 8 - Commitments (Details Textual)	Sep. 30, 2018USD ($)ft²
Area of Real Estate Property | ft²	8,400
Operating Leases, Future Minimum Payments Due, Total	$ 200,402
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	39,136
Operating Leases, Future Minimum Payments, Due in Two Years	161,266
Unrecorded Unconditional Purchase Obligation, Total	$ 209,000

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended
	Sep. 30, 2018	Mar. 31, 2018	Feb. 28, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 05, 2018	Dec. 31, 2017
Conversion of Stock, Shares Converted						1,000	178
Conversion of Stock, Shares Issued						66,666,666	11,862,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01			$ 0.01		$ 0.01			$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			178,571
Warrants and Rights Outstanding, Term			5 years
Stock Issued During Period, Shares, Issued for Services			5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.042	$ 0.001		$ 0.001			$ 0.001
Class of Warrant or Right, Outstanding	0			0		0
Employee Stock Option [Member]
Allocated Share-based Compensation Expense, Total				$ 85,370	$ 14,433	$ 132,569	$ 43,535
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 145,230			145,230		$ 145,230
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition						1 year 328 days
Common Stock Issued For Services [Member]
Allocated Share-based Compensation Expense, Total				57,143		$ 142,856
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 57,143			$ 57,143		$ 57,143
Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								47,169,812
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.02544
Warrants and Rights Outstanding, Term								3 years
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	100			100		100			100
Convertible Preferred Stock, Conversion Price1	$ 0.35			$ 0.35		$ 0.35
Convertible Preferred Stock, Total Conversion Shares	285,714			285,714		285,714
Conversion of Stock, Shares Converted						0
Preferred Stock, Par or Stated Value Per Share	$ 1,000			$ 1,000		$ 1,000			$ 1,000
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	2,570			2,570		2,570			2,570
Convertible Preferred Stock, Conversion Price1	$ 0.015			$ 0.015		$ 0.015
Convertible Preferred Stock, Total Conversion Shares	171,349,733			171,349,733		171,349,733
Conversion of Stock, Shares Converted						0
Preferred Stock, Par or Stated Value Per Share	$ 1,000			$ 1,000		$ 1,000			$ 1,000
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	0			0		0			1,000
Conversion of Stock, Shares Converted						1,000
Conversion of Stock, Shares Issued						66,666,666
Preferred Stock, Par or Stated Value Per Share	$ 1,000			$ 1,000		$ 1,000			$ 1,000
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	1,200			1,200		1,200			0
Convertible Preferred Stock, Conversion Price1	$ 0.02544			$ 0.02544		$ 0.02544
Conversion of Stock, Shares Converted		600				0
Preferred Stock, Par or Stated Value Per Share	$ 1,000	$ 1,000		$ 1,000		$ 1,000			$ 1,000
Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost	$ 600,000	$ 590,000
Stock Issued During Period, Shares, New Issues	600

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Activity of Stock Option Plan (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Outstanding, options (in shares) | shares	7,024,275
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.29
Granted, options (in shares) | shares	3,000,000
Granted, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.03
Forfeited or expired, options (in shares) | shares	(169,334)
Forfeited or expired, weighted average exercise price, options (in dollars per share) | $ / shares	$ 2.46
Outstanding, options (in shares) | shares	9,854,941
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.17
Exercisable, options (in shares) | shares	4,890,618
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.29

Note 11 - Grants and Collabor_2

Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue from Contract with Customer, Including Assessed Tax	$ 349,344	$ 247,994	$ 663,908	$ 895,866
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	340,716	247,994	650,280	800,866
Unused Grant Funds	2,873,542		2,873,542
Government Contract [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 8,628	$ 0	$ 13,628	$ 95,000

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)	1 Months Ended		6 Months Ended	9 Months Ended
	Oct. 31, 2018	Feb. 28, 2018	Mar. 31, 2019	Jun. 30, 2019	Sep. 30, 2018	Sep. 30, 2017
Stock Issued During Period, Shares, Issued for Services		5,000,000
Conversion of Stock, Shares Converted					1,000	178
Conversion of Stock, Shares Issued					66,666,666	11,862,000
Common Stock Issued for Capital Market and Business Advisory Services [Member] | Scenario, Forecast [Member]
Allocated Share-based Compensation Expense, Total			$ 129,750
Common Stock Issued for Financial Advisory and Investment Banking [Member]
Accrued Cash Retainer Fees					$ 56,250
Common Stock Issued for Financial Advisory and Investment Banking [Member] | Scenario, Forecast [Member]
Allocated Share-based Compensation Expense, Total				$ 127,500
Subsequent Event [Member] | Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted	90
Conversion of Stock, Shares Issued	6,000,000
Subsequent Event [Member] | Common Stock Issued for Capital Market and Business Advisory Services [Member]
Stock Issued During Period, Shares, Issued for Services	5,000,000
Subsequent Event [Member] | Common Stock Issued for Financial Advisory and Investment Banking [Member]
Stock Issued During Period, Shares, Issued for Services	7,500,000